Drug Use in Pregnancy. Principal Problems and a Review of Newer Utilization Studies

References

• McBride W. G. Thalidomide and congenital abnormalities. Lancet 1961; ii: 1358
   Google Scholar
• Ward R. M. Maternal-placental-fetal unit: unique problems of pharmacologic study. Pediatr. Clin. North. Am. 1989; 36: 1075–1088
   PubMed Web of Science ®Google Scholar
• Peters P. W.J. Risk assessment of drug use in pregnancy: prevention of birth defects. Ann. ist Super Sanita 1993; 29: 131–137
   PubMedGoogle Scholar
• Rubin P. C. Prescribing in pregnancy, general principles. BMJ 1986; 293: 1415–147
   PubMed Web of Science ®Google Scholar
• Peters P. W.J., Garins-Berkvens H. M., Bannigan J. G. Drug of choice in pregnancy: primary prevention of birth defects. Reprod. Toxicol. 1993; 7: 399–404
   PubMed Web of Science ®Google Scholar
• Joffe J. M., Soyka L. F. Paternal drug exposure effects on reproduction and progeny. Semin. Perinat. 1982; 6: 116–124
   PubMed Web of Science ®Google Scholar
• Finastride for benign prostatic hypertrophy. Drug. ther. Bull. 1995; 33: 19
   PubMedGoogle Scholar
• Drugs and the fetus, Editorial. BMJ 1996; 312: 1053–1054
   PubMed Web of Science ®Google Scholar
• Hanauer S. B., Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug-Saf. 1991; 6: 192–219
   PubMed Web of Science ®Google Scholar
• Sørensen H. T. Farmakologisk epidemiologi (Pharmacological epidemiology). Ugeskr. Laeg. 1993; 155: 207
   PubMedGoogle Scholar
• Danish National Board of Health, Personal communication
   Google Scholar
• Jelovsek F. R., Mattison D. R., Chen J. J. Prediction of risk for human developmental toxicity: how important are animal studies for hazard identification. Obstet. Gynecol. 1989; 74: 624–626
   PubMed Web of Science ®Google Scholar
• Wiholm B-E., Olsson S., Moore N., Wood S. Spontaneous reporting systems outside the United States. Pharmacoepidmiology, B. L. Strom. Wiley, Chichester 1994
   Google Scholar
• Khoury M. J. Epidemiology of birth defects. Epidemiol. Rev. 1989; 11: 244–248
   PubMed Web of Science ®Google Scholar
• Slone D., Siskind V., Heinonen O. P., Monson R. R., Kaufman D. W. Shapiro, S., Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am. J. Obstet. Gynecol. 1977; 128: 486–488
   PubMed Web of Science ®Google Scholar
• Stika L., Elisova K., Honzakova L. Effects of drug administration in pregnancy on children's school behaviour. Pharm. Weekbl. Sci. 1990; 12: 252–255
   PubMedGoogle Scholar
• Pasker-de Jong P. Medication during pregnancy, thesis. Nijmegen 1993
   Google Scholar
• Reinisch J. M., Sanders S. A., Mortensen E X, Rubin D. B. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274: 1518–1525
   PubMed Web of Science ®Google Scholar
• Herbst A. L., Ulfelder H., Poskanzer D. C. Association of maternal stilbestrol therapy with tumor appearance in young women. N. Eng. Med. 1971; 284: 878–881
   PubMed Web of Science ®Google Scholar
• Herbst A. L., Cole P., Norusis M. J., Welch W. R., Scully R. E. Epidemiologic aspects and factors related to survival in 384 registry cases of clear cell adenocarconoma of the vagina and cervix. Am. J. Obstet. Gynecol. 1979; 135: 876–883
   PubMed Web of Science ®Google Scholar
• Jick H., Holmes L. B., Hunter J. R., Madsen S., Stergachis A. First trimester drug use and congenital disorders. JAMA 1981; 246: 343–346
   PubMed Web of Science ®Google Scholar
• Aselton P., Jick H., Milunsky A., Hunter J. R., Stergachis A. First-trimester drug use and congenital disorders. Obstet. Gynecol. 1985; 65: 451–455
   PubMed Web of Science ®Google Scholar
• Bergman U., Rosa F. W., Baum C., Wiholm B-E., Faich G. A. Effects of exposure to benzodiazepine during fetal life. Lancet 1992; 340: 694–6
   PubMed Web of Science ®Google Scholar
• Lechat M. F., Dolk H. Registries of congenital anomalies: EUROCAT. Environ Health Perspect 1993; 100(suppl 2)153–157
   Google Scholar
• de Jong-van den Berg L. T.W. Drug utilization studies in pregnancy. STYX Publications, Groningen 1992, Thesis
   Google Scholar
• Doucette J. T., Brachen M. B. Possible role of asthma in the risk of preterm labor and delivery. Epidemiology 1993; 4: 143–150
   PubMed Web of Science ®Google Scholar
• Lindhout D., Omtzigt J. G. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35(Suppl. 4)S19–28
   PubMed Web of Science ®Google Scholar
• Kitzmiller J. L., Gavin L. A., Gin G. D., Jovanovic-Peterson L., Main E. K., Zigrang W. D. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991; 265: 731–6
   PubMed Web of Science ®Google Scholar
• Mitchell A. A., Cottier L. B., Shapiro S. Effects of questionnaire design on recall of drug exposure during pregnancy. Am. J. Epidemiol. 1986; 123: 670–676
   PubMed Web of Science ®Google Scholar
• Bryant H. E., Visser N., Love E. J. Records, recall loss and recall bias in pregnancy: A comparison of interview and medical records data of pregnant and postnatal women. Am. J. Public Health 1989; 79: 78–80
   PubMed Web of Science ®Google Scholar
• Bonati M., Bortulus R., Machetti F., Romere M., Tognoni G. Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur. J. Clin. Pharmacol. 1990; 38: 325–328
   PubMed Web of Science ®Google Scholar
• Collaborative group on drug use in pregnancy (C.G.D.U.P). Medication during pregnancy: an intercontinental cooperative study. Int. J. Gynecol. Obstet. 1992; 39: 185–96
   PubMed Web of Science ®Google Scholar
• Marchetti F., Romero M., Bonati M., Tognoni G. Use of psychotropic drugs during pregnancy. Eur. J. Clin. Pharmacol. 1993; 45: 495–501
   PubMed Web of Science ®Google Scholar
• Rubin J. D., Ferencz C. Loffredo, C. and the Baltimore-Washington infant study group, Use of prescription and non-prescription drugs in pregnancy. J. Clin. Epidemiol 1993; 46: 581–589
   PubMed Web of Science ®Google Scholar
• Hemminki E., Mäntyranta T., Malin M., Koponen P. A survey on the use of alternative drugs during pregnancy. Scand. J. Soc. Med. 1991; 19: 199–204
   PubMedGoogle Scholar
• de Jong-van den Berg L. T., van den Berg P. B., Peters P. W.J., Haaijer-Ruskamp F. M. A study of drug utilisation during pregnancy in the light of known risks: is there room for improvement. Int. J. Risk. Saf. Med. 1990; 1: 91–105
   Google Scholar
• McDonald A. D. Therapeutic drugs in early pregnancy and congenital defects. J. Clin. Epidemiol 1994; 47: 105–110
   PubMed Web of Science ®Google Scholar
• Rothman K. J., Moore L. L., Singer M. R., Nguyen U. S.T., Mannini S., Milunsky A. Teratogenicity of high vitamin A intake. N. Engl. J. Med. 1995; 333: 1369–1373
   PubMed Web of Science ®Google Scholar
• European Community, Proposal categorization of medicinal products in pregnancy for the Committee of Proprietary Medicinal Products. European Community, Brussels 1991
   Google Scholar
• Zhou W., Nielsen G. L., Steffensen F., Sørensen H. T., Olsen J. Preliminary data on exposure to prescribed, reimbursed drugs among 6140 Danish pregnant women. Abstract no. 175. First meeting of EURO DURG 1996, , Hungary, 1996
   Google Scholar